Telix Pharmaceuticals (TLX1N) AI Stock Analysis

Telix Pharmaceuticals

(BMV:TLX1N)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong commercial growthSustained double-digit growth across the group and core Precision Medicine franchise indicates expanding commercial adoption rather than reliance on a single temporary gain. Continued growth at this scale can strengthen operating leverage, support pipeline investment, and broaden Telix’s revenue base over the next several quarters.

Negative Factors

Recent cash-flow reversalThe reversal into negative operating and free cash flow weakens cash conversion and increases reliance on financing while the company continues investing in growth. If sustained, it could constrain reinvestment flexibility and make execution more sensitive to spending levels, working capital needs, and product timing.

Telix Pharmaceuticals (TLX1N) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 3.04B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 96.6
Beta (1Y): -0.80
Revenue Growth: 21.03%
EPS Growth: 165.12%
Country: Mexico
Employees: 1,152
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Telix Pharmaceuticals Business Overview & Revenue Model

Company Description

Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare condit...

Telix Pharmaceuticals Earnings Call Summary

Earnings Call Date:Aug 18, 2026(Q2-2026)|% Change Since:0.00%|Next Earnings Date:Oct 18, 2022

Earnings Call SentimentPositive

The call highlighted multiple strong commercial and clinical positives: double‑digit revenue growth (H1 revenue $477M, +22% YoY), robust Precision Medicine momentum (~$390M, +27% YoY), improving margins, a solid cash position ($252M), near-term regulatory catalysts (Pixclara PDUFA on 11 Sep) and advancement of Phase III therapeutic programs and the BiPASS study. Offsetting these are material regulatory uncertainties (notably the Zircaix CRL and required resubmission to address third‑party manufacturing deficiencies), timing risk for European approvals, higher near‑term R&D spend ($230M–$270M guidance) and competitive/reimbursement dynamics. Overall, the highlights — including strong commercial execution, product launches, pipeline progress and strategic partnerships — materially outweigh the lowlights, though execution against regulatory milestones and funding of increased R&D spend remain key watch items.

Positive Updates

Strong Top-Line Growth

Reported group revenue of $477 million for H1 2026, up 22% year-on-year, driven by robust commercial execution in the Precision Medicine franchise.

Negative Updates

Zircaix Regulatory Setback and Resubmission Requirement

Zircaix received a corrected Complete Response Letter (CRL) from the FDA related to third-party manufacturing deficiencies. Management said the resubmission is a top priority and is expected 'very soon' (company control), but the CRL represents a material regulatory hurdle and timing uncertainty for this asset.

Company Guidance

Management reiterated FY2026 revenue guidance of $950–$970m (saying they expect to land at the upper end) after reporting H1 revenue of $477m (+22% YoY) with Precision Medicine sales ~ $390m (+27% YoY) and Precision Medicine gross margin at 65% (consolidated gross margin 55%). They updated R&D guidance to $230–$270m (R&D was 26% of H1 revenue), noted Precision Medicine growth is expected to exceed 20% YoY and that cash was $252m following a convertible bond refinance. H1 EBITDA was $52m (up 146% YoY) with net profit after tax $38m, OpEx fell 1% as a percentage of sales, TMS third‑party revenue was $89m (+10% YoY) and internal RLS revenues were $57m (+70% YoY). Near‑term regulatory timelines cited include a U.S. PDUFA date for Pixclara on Sept 11, a Zircaix resubmission expected in the next 1–2 months, and clinical readouts driven by event‑based triggers (e.g., ProstACT Part 2 interim analysis at 81 progression events) and BiPASS nearing targeted enrollment.

Telix Pharmaceuticals Peers Comparison

Overall Rating

Financial Indicators

MX:TLX1N against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:TLX1N and its peers over the selected period
Show on chart	Ticker	Company Name	Price	Change	% Change
	MX:TLX1N	Telix Pharmaceuticals Ltd.	302.55	0.00	0.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Telix Pharmaceuticals AI Stock Analysis